A new research study from the Robert Wood Johnson Medical School showed that niclosamide ethanolamine salt (NEN) can burn the excess fat in the liver cells of mice through a process known as mitochondrial uncoupling. Fat accumulation in the liver is a typical characteristic of diabetic patients.
Type 2 diabetes affects an estimated 28 million Americans according to the American Diabetes Association, but medications now available only treat symptoms, not the root cause of the disease. New research from Rutgers shows promising evidence that a modified form of a different drug, niclosamide — now used to eliminate intestinal parasites – may hold the key to battling the disease at its source.
Nature Medicine
The study, led by Victor Shengkan Jin, an associate professor of pharmacology at Rutgers Robert Wood Johnson Medical School, has been published online by the journal .
Jin says it is important to find a suitable medication to correct the cause of the disease as quickly as possible because the only way now known to "cure" the disease involves major gastric bypass surgery. "The surgery can only be performed on highly obese people," Jin explains, "and carries significant risks that include death, so it is not a realistic solution for most patients."
Link to the report on MedicalXpress: http://bit.ly/1oJNOh6
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen